Drug Profile


Alternative Names: Captisol®-enabled pevonedistat; MLN-4924; TAK-924

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Takeda Oncology
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Cyclopentanes; Indenes; Pyrimidines; Pyrroles; Small molecules; Sulfonic acids
  • Mechanism of Action NEDD 8 activating enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase I Solid tumours
  • No development reported Haematological malignancies

Most Recent Events

  • 23 Feb 2017 Millennium Pharmaceuticals plans a phase I trial for Solid tumours (NCT03057366)
  • 30 Dec 2016 City of Hope Medical Center and National Cancer Institute plan a phase I trial for Acute myeloid leukaemia (Combination therapy) in USA (IV) (NCT03009240)
  • 03 Dec 2016 Efficacy, adverse events and pharmacokinetics data from phase I trial in Acute myeloid leukaemia (Combination therapy) presented at the Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top